• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
FIJ 4.76% 11.0¢

FIJI KAVA LIMITED - Corporate Spotlight

Fiji Kava is a medicinal Noble kava company based in Australia pioneering safe... Fiji Kava is a medicinal Noble kava company based in Australia pioneering safe alternatives to prescription medicines and natural therapies. FIJ recently signs national agreement with Australian therapeutics giant Blackmores owned subsidiary BioCeuticals Limited. This follows the nation wide launch in COLES of their ‘Noble Kava’ range.More

Corporate Spotlight

Fiji Kava is a medicinal Noble kava company based in Australia, providing a natural solution to calm and soothe nerves, support muscle relaxation, increase mind relaxation and induce sleep.
View the full Corporate Spotlight arrow Created with Sketch.

FIJI KAVA SIGNS MOU TO EXPLORE DIRECT SUPPLY CHINA

FIJ ACHIEVES RECORD REVENUE FOR MARCH

arrow-down-2 Created with Sketch.

Fiji Kava (ASX:FIJ) achieves record revenue result for March quarter

Health Care

ASX:FIJ 
Fiji Kava (ASX:FIJ) appoints Jack Lowenstein as Non-Executive Director
Source: Fiji Kava

  • Fiji Kava (FIJ) raked in over $400,000 in revenue during the March quarter and signed a key distribution deal
  • The healthcare stock released its quarterly update on Thursday, showing it notched up a 160 per cent increase in revenue year-on-year
  • The company also signed an agreement with Chemist Warehouse to have its Noble Kava capsules stocked in-store and online
  • Fiji ended March with $2.33 million worth of cash in the bank, slightly down on the previous quarter, but the company did manage to reduce its expenditure
  • Shares in FIJ are trading up 4.17 per cent at 12.5 cents per share

Fiji Kava (FIJ) has revealed it raked in over $400,000 in revenue during the March quarter while signing a key distribution deal with a major retailer.


The healthcare stock released its quarterly update on Thursday, showing it notched up a 160 per cent increase in revenue year-on-year.


Its total revenue over the three-month period was $405,042, which also represents an increase of 27 per cent from the December quarter.


"I am pleased to announce that Fiji Kava has recorded another record quarterly revenue result and continued to deliver quarter-on-quarter revenue growth," CEO Nicholas Simms said.


"We enter Q4 with growing momentum and with the company having already surpassed FY20 full-year revenues," the FIJ leader added.


Another development during the quarter involved signing an agreement with Chemist Warehouse to have its Noble Kava capsules stocked in store.


The deal with the major chemist retailer will see Fiji Kava's range stocked across Australia, New Zealand and online stores, with the rollout beginning this month.


"The pharmacy network is a critical channel for consumers seeking remedies for sleep, mild anxiety and other mind and body ailments, and so we're delighted to have secured ranging within Australia's largest pharmacy retailer," Nicholas said.


Financially, Fiji has revealed it ended March with $2.33 million worth of cash in the bank, slightly down on the previous quarter when it had $3.37 million in the bank.


However, the company said it did manage to reduce its expenditure over the period thanks to an increase in cash receipts.


At the end of Q3, the healthcare stock said it had enough cash to keep the company running for another 2.27 quarters.


Following today's update, Fiji Kava shares are trading up 4.17 per cent at 12.5 cents per share at 3:36 pm AEST.



Read the full article on The Market Herald here.

FIJ SEES A POSITIVE SIX MONTHS OF FY21

arrow-down-2 Created with Sketch.

Fiji Kava (ASX:FIJ) sees a positive six months of FY21

Mining

ASX:FIJ   
Fiji Kava (ASX:FIJ) - Founder, Zane Yoshida - The Market Herald
Founder, Zane Yoshida

  • Health and wellness company Fiji Kava (FIJ) has recorded a record revenue for the first six months of the 2021 financial year
  • The company reported revenue of just over $496,000, which us up 11 per cent from the first half of the 2020 financial year
  • Fiji had a net loss of $1.5 million, which is a 28 per cent improvement from the prior corresponding period
  • Over the period, the company signed a licence agreement with Blackmores and entered the Chinese market after signing an exclusive distributor agreement with PuMate

Fiji Kava (FIJ) has a record revenue for the first six months of the 2021 financial year, despite impacts from the COVID-19 pandemic and Cyclone Yasa. 


The health and wellness company recorded revenue of $496,379, which us up 11 per cent from the first half of the 2020 financial year. 


Fiji had a net loss of $1.5 million, which is a 28 per cent improvement from the prior corresponding period. 


Over the period, the company signed a licence agreement with Blackmores and entered the Chinese market after signing an exclusive distributor agreement with PuMate. 


In October, Fiji signed a memorandum of understanding with Shanghai-listed Yuan Long Yato, who provides digital marketing services to well-known clients such as Nestle and the 2022 Winter Olympic Games. 


More recently, in its December quarterly report, the company saw strong results in its revenue. 


"We made positive progress in the availability of Fiji Kava and the company is well positioned to capture its share of the growing international opportunity for Noble Kava Extract and Powders, including growth in both our existing markets and exploration into new markets for the future," CEO Nicholas Simms said. 


"We have achieved this despite a challenging external environment. Pleasingly, some supply chain operations appear to be normalising and we have undertaken repairs for minor damage sustained at the company’s facilities in Levuka, on the island of Ovalau, caused by Cyclone Yasa," he added.

 

Total assets for Fiji was $5.5 million, which is a 89 per cent improvement to the previous corresponding period of $2.9 million. 



Read the full article on The Market Herald here.

FIJ INCREASES REVENUE BY 94% IN DEC QTR

arrow-down-2 Created with Sketch.

Fiji Kava (ASX:FIJ) increases revenue by 94pc in December quarter

Consumer, Health Care

ASX:FIJ    
Fiji Kava (ASX:FIJ) appoints Jack Lowenstein as Non-Executive Director

Source: Fiji Kava

  • Fiji Kava (FIJ) has recorded some strong results in its December quarterly report, including a 94 per cent increase in revenue
  • The noble kava producer brought in over $319,000 over the three month period, compared to $164,000 during the September quarter
  • Activities wise, the company successfully completed its first order with PuMate, marking its entry into the Chinese market
  • It also signed a deal with Yuan Long Yato to potentially market and distribute more products in the region
  • Additionally, Fiji recorded sales growth for its different kava products sold within Coles Supermarkets (COL) 
  • Fiji Kava ended Q2 FY21 with $3.37 million worth of cash in the bank



Fiji Kava (FIJ) has recorded some strong results in its latest quarterly report, including a 94 per cent increase in revenue.


The noble kava producer brought in over $319,000 in revenue over Q2 FY21, up from $164,000 in revenue during the previous quarter.


When compared to Q2 FY20, the revenue growth was even more significant — increasing 96 per cent year-on-year.


Activities wise, it was a busy few months for the company which completed its first orders into China via its deal with PuMate.


Fiji Kava also signed a memorandum of understanding (MoU) with Shanghai-based Yuan Long Yato to potentially market and distribute more of FIJ's products in the region.


In addition to these developments, the company said Q2 saw sales growth for its multiple products being sold within Coles Supermarkets (COL).


FIJ sells its Fiji Kava Noble Kava Extract and three new noble Kava varieties of 'Sleep', 'Mind' and 'Body' capsules across hundreds of the Australian supermarket chain's stores.


Commenting on the December quarter's activities, Fiji Kava CEO Nicholas Simms said he is expecting more growth in the coming year.


"This has been a positive quarter for Fiji Kava with positive revenue and the announcements of material new agreements to grow the availability of our products globally," he said.


"While the nature of our business, the timing of new agreements and other external factors can result in short-term revenue fluctuations in any given quarter, we anticipate growing momentum over the medium to long-term," he added.


Fiji Kava ended Q2 FY21 with $3.37 million worth of cash in the bank, enough funding to keep the company going for another 2.62 quarters.


That's assuming its spend rate stays the same, with the company burning through $1.28 million during the December quarter.


Read the full article on The Market Herald here.

FIJI KAVA SIGNS MOU EXPLORE CHINA TRADE

arrow-down-2 Created with Sketch.


Fiji Kava (ASX:FIJ) signs MoU with Yuan Long Yato

Consumer Discretionary

ASX:FIJ    

Fiji Kava (ASX:FIJ) - Interim CEO, Nicholas Simms - The Market Herald

Interim CEO, Nicholas Simms

  • Fiji Kava (FIJ) has signed a Memorandum of Understanding (MoU) with Shanghai listed Yuan Long Yato
  • Yuan Long Yato provides digital marketing services to well-known clients such as Nestle and the 2022 Winter Olympic Games
  • This MoU will enable Fiji Kava to explore the marketing and distribution of its products to online platforms and networks in China
  • Additionally, it is an important step in growing the company's brand in China's $30 billion vitamins and supplement market 
  • Fiji Kava specialises in kava which is a medicinal drug native to the South Pacific which relaxes muscles and induces feelings of wellbeing



Fiji Kava (FIJ) has signed a Memorandum of Understanding (MoU) with Shanghai listed Yuan Long Yato. 


This MoU will enable Fiji Kava to explore the marketing and distribution of its products to online platforms and networks throughout China. 


Additionally, it is an important step in growing the company's brand in China's estimated RMB149 billion (around A$30 billion) vitamin and supplement market. 


Yuan Long Yato provides digital marketing services, via means such as social media and WeChat, to well-known clients such as Nestle and the 2022 Winter Olympic Games. 


"Following the announcement of our landmark partnership to enter the Chinese market with PuMate, we are delighted to explore online platforms and direct network opportunities with a company of Yuan Long Yato's expertise, experience and standing in the Chinese market," Interim CEO Nicholas Simms said. 


Fiji Kava is an Australia-Fijian medicinal kava health and wellness company which produces natural 'Noble Kava' products. 

Kava is a drug made from the ground roots of the Piper methysticum, a plant from the pepper family, and is native to the South Pacific. 

The root is traditionally crushed, ground or powdered and soaked in water to be drunk as tea. This tea is often consumed socially as part of traditional ceremonies and cultural practices throughout the Pacific Islands. 


In small doses kava can help relax muscles and induce feelings of wellbeing and sleepiness, however, long-term use can lead to a range of problems such as weight loss, malnutrition, and indifference. 


Noble kava is considered the safest form to consume. 




Read the full article on The Market Herald here.

FIJ CODEX REGIONAL KAVA STANDARD ADOPTED

arrow-down-2 Created with Sketch.



Fiji Kava (ASX:FIJ) embraces new regional Kava standard ahead of commercial trial

Consumer Discretionary

ASX:FIJ   

Fiji Kava (ASX:FIJ) - CEO & Founder, Zane Yoshida - The Market Herald

CEO & Founder, Zane Yoshida
Source: Fiji Kava


  • Fiji Kava (FIJ) says a new regional Kava standard by the Codex Alimentarius Commission will strengthen its strategy to sell Noble Kava through its end-to-end supply chain
  • The standard is supported by a number of global organisations and is expected to significantly bolster regulations for the Pacific Noble Kava market
  • It outlines procedures and controls for growing, harvesting and producing high-quality Kava products
  • The standard comes ahead of an Australian commercial importation trial, anticipated to begin by December 2021
  • Shares in Fiji Kava remain grey at market open, priced at 24.5 cents per share



Fiji Kava (FIJ) says a new regional Kava standard by the Codex Alimentarius Commission will strengthen its strategy to sell Noble Kava through its end-to-end supply chain.


Established with the support of the Food and Agriculture Organisation, the United Nations and the World Health Organisation, the standard is expected to significantly bolster regulations for the Pacific Noble Kava market.


It excludes other Kava varieties, such as Tudei Kava, and outlines procedures and controls for the growth, harvesting and processing of safer, higher-quality Kava for international exports.


Codex’s adoption of the standard follows a five-year process which began in 2016 and has now been finalised after successfully passing through eight stages of approval.


Zane Yoshida, CEO of Fiji Kava, is a member of Fiji’s National Codex Committee and played a central role in the development of the new standard.


“Fiji Kava only sells Noble Kava as the highest quality and safest varieties of Kava, which we grow and export via our vertically integrated supply chain,” Zane said.


“While many exporters will be forced to make changes to their business in response to the standard, Fiji Kava will continue to operate with complete confidence in our strategy to sell our Fijian Noble Kava across international markets,” he added.


The roll-out of the new standard comes ahead of an Australia commercial importation trial for Kava products. This trial was previously delayed due to the outbreak of COVID-19 but has now been confirmed to begin by December next year.


Anticipated to broaden consumer access to Kava, it follows an expanded pilot program initiated by the Australian Government in December 2019, which increased personal imports from two kilograms to four kilograms per passenger.


“We are strongly positioned to participate in the trial and to work with government in the trial’s development ahead of its launch next year,” Zane concluded.


Shares in Fiji Kava remain grey at market open, priced at 24.5 cents per share at 10:14 am AEDT.


Read the full ASX Release Here

NATURAL ALTERNATIVE FOR GLOBAL MARKET

arrow-down-2 Created with Sketch.

Fiji Kava (ASX:FIJ): The natural alternative for the $100B global sleep and anxiety market

Sponsored

Fiji Kava (ASX:FIJ) appoints Jack Lowenstein as Non-Executive Director
Source: Fiji Kava


  • Millions of Australians currently suffer from poor sleep and anxiety, and the market to fix these issues is expected to be worth US$114 billion (around A$154 billion) by 2025
  • The Federal Government has also recognised this is a growing problem, investing more than $5.2 billion into the sector in 2020
  • While all mental illnesses require professional treatment, there is a growing industry of complementary medicines
  • The medicines aren't designed to treat an illness, but rather the less extreme symptoms that accompany some mental health issues
  • The complementary medicine market is already worth $4.2 billion annually and is expected to grow even further as the focus shifts to improving Australians' wellbeing
  • Cannabis and its by-products have been a big disruptor of the complementary medicines market, but now a new plant promises to change the market again
  • The product is the Noble Kava, which Fiji Kava (FIJ) has spent years perfecting
  • Fiji Kava's products are now being sold at Coles, while Blackmores has licensed its medicine for one of its own AnxioCalm products
  • Fiji's shares are trading for 24.5 cents on the ASX

Stress, anxiety and poor sleep habits are issues many Australians confront daily, but the market for treating these ailments is growing.


A recent estimate found the sleep aid market would be worth US$114 billion (around A$154 billion) by 2025. In 2018, that market was valued at US$71.04 billion (about A$99.05 billion)


The issue

Right now in Australia, an estimated 14 per cent of the population will suffer anxiety over their lifetime, according to Mindframe.


That number grows when you examine sleep issue, with the Sleep Health Foundationestimating that more than half of adult Australians are currently suffering from at least one chronic sleep symptom.


The issue of anxiety and poor sleep has even been recognised by the Federal Government, who have announced plans to funnel more than $5.2 billion into the wider mental health sector.


This money will go towards helping those who have ongoing mental illnesses receive better support from their psychologists, psychiatrists or even just their GPs. It will also be spent on better educating Australians about the issue of mental health and wellbeing.


The focus by officials here isn't just mental illnesses, but wider mental health - which is defined as being a person's overall wellbeing and how they're coping with life's stresses.


But, while all mental illnesses require treatment by professionals, there is also room for complementary medicines to assist in the treatment of mental health issues.


The other treatments

These therapies don't target illnesses, nor are they prescription medications, instead, they try and offer relief for some of the less extreme side effects which go hand-in-hand with mental distress.


Complementary medicine is also a growing market, with estimations by industry body Complementary Medicines Australia (CMA) showing the market turned over $4.2 billion in revenue in 2018 alone, which is $2 billion in growth over five years.


The demand for complementary medicines can also be seen abroad, with Australia current exporting just under $1 billion worth of these medicines overseas in 2019. China and Hong Kong are the biggest markets, followed by New Zealand, Vietnam and South Korea.


So far, cannabis and its by-products have been a big disruptor of the complementary medicines market, but now a new plant promises to change the market again.


The product is Noble Kava, which Fiji Kava (FIJ) has spent years perfecting, successfully taking the traditional medicine used by the Fijian people for centuries into the mainstream.


Fiji has created a range of products containing kavalactones, which are found in the root of only select varieties of Noble kava plants, and work to increase body relaxation, induce sleep, as well as calm and soothe the nerves.


The company's Scientific Advisor, and part of the NICM Health Research Institute at Western Sydney University, Professor Jerome Lassar, said complementary medicines have never been more timely.


Kava's products, which are approved for use in Australia by the TGA as a complementary medicine, can be used by themselves or alongside other traditional therapies.


"The Fijian plant medicine Kava has a valuable role alongside standard medications, psychological care, and healthy lifestyle choices, in assisting with the management of anxiety," Jerome added.


The market

The demand for complementary medicines is evidenced by Fiji Kava's recent deal with ASX-200 company Coles Group (COL). The supermarket giant recently began selling Fiji's Noble Kava Capsules in its Coles stores across the country, the first global retailer to do so.


Coles isn't the only ASX-200 company taking notice of Kava, with Blackmores and Fiji Kava recently signing an agreement to have its noble Kava extract used in Blackmore' BioCeuticals Clinical AnxioCalm product.


Speaking about the agreement, Fiji Kava Founder and CEO Zane Yoshida said he was pleased to see a business as big as Blackmores recognise the quality of their Noble Kava ingredients.


"This is another milestone for the company that will not only increase the availability of our noble kava in Australia and New Zealand, but is another strong endorsement by a leading healthcare provider of the quality and uniqueness of our Fijian noble kava," he said.


Fiji's shares are trading for 24.5 cents on the ASX.


Read the full article on The Market Herald here: https://hotcopper.com.au/threads/fiji-kava-the-natural-alternative-for-the-100b-global-sleep-and-anxiety-market.5575955/

FIJ SIGNS AGREEMENT WITH BLACKMORES BIO

arrow-down-2 Created with Sketch.



FIJI KAVA SIGNS MAJOR AGREEMENT WITH BLACKMORES OWNED BIOCEUTICALS

ASX Release 13th August 2020


  • First major collaboration to supply Fiji Kava’s high-quality noble kava extract under licence agreement

  • BioCeuticals is the #1 Practitioner brand in Australia and proudly owned by leading Australian healthcare

    and ASX200 company, Blackmores Limited

  • The agreement will see a BioCeuticals licence the use of Fiji Kava's high quality noble kava extract for its BioCeuticals Clinical AnxioCalm product

  • BioCeuticals is renowned for manufacturing and delivering high quality integrative medicines to healthcare practitioners in Australia, New Zealand and the United States

  • Fiji Kava’s sustainable, unadulterated and 100% traceable supply chain of ‘noble kava’ delivers key differentiation, resulting in interest from market leading brands and retailers


Fiji Kava Ltd (ASX: FIJ), an Australian-Fijian medicinal kava health and wellness company which produces natural ‘noble kava’ products for the complementary and alternative medicine market, today announces a non-exclusive licence agreement with BioCeuticals, a Blackmores-owned company, to develop a co-branded product for release in Australia and New Zealand.


The agreement will see BioCeuticals licence the use of Fiji Kava's high quality noble kava extract for its BioCeuticals Clinical AnxioCalm product, which is a unique blend of herbs to support symptomatic relief of mild anxiety, tension and stress, formulated to calm and support the nervous system and to minimise stress.


The AnxioCalm products will be co-branded with Fiji Kava’s ‘Authentic Fiji Kava’ trademark clearly and prominently displayed on each product sold. The AnxioCalm products will be available through BioCeuticals extensive network of qualified healthcare practitioners across Australia and New Zealand.


Founder and CEO, Mr Zane Yoshida, said: “This is another milestone for the company that will not only increase the availability of our noble kava in Australia and New Zealand, but is another strong endorsement by a leading healthcare provider of the quality and uniqueness of our Fijian noble kava.


"In particular, we are proud to support BioCeuticals with our water extracted Noble Fiji Kava, as allowed by the TGA in Australia. We are able to deliver this to BioCeuticals and our other partners through our vertically integrated supply chain, guaranteeing a sustainable and 100% traceable supply of unadulterated Noble Fiji Kava.


"Fiji Kava will continue to scale-up its production in Fiji to produce required inventory to meet the growing demand from the BioCeuticals licence agreement and other recent business development advancements such as ranging in Coles Supermarkets nationally."


The agreement with BioCeuticals continues a period of strong and sustained progress being made by the company on its commercial strategy to grow the availability of its Fijian noble kava. The company now has cornerstone retail agreements in place in targeted markets, such as Coles Supermarkets in Australia and Green Cross Pharmacy in New Zealand; and has expanded its e-commerce presence on Amazon in the

United States, while exploring opportunities to access Chinese marketplaces.
Fiji Kava will supply BioCeuticals with its noble kava via its agreement with Pathway International


Read the full ASX Release Here

VIABILITY OF KAVA IN HEALTHCARE

arrow-down-2 Created with Sketch.

28th July 2020 - The Market Herald


  • A muscle relaxing drink from the Pacific Islands could be seeing a resurgence in the alternative medicine market
  • The drink called Kava is taken from a plant's root and can be used in curbing anxiety and give feelings of euphoria
  • Australian listed company Fiji Kava (ASX:FIJ) is trying its best to catch the wave that is seeing kava put in bars, clubs, alternative dining, and in fringe culture
  • Fiji Kava signed on a new deal with natural medicine supplier Oborne Health Supply today — which will see further distribution of its Kava properties in pill form
  • Shares in small cap Fiji Kava have achieved a valuation of 10.5 cents each after a five per cent premium today

A Pacific Island muscle relaxant drink has made its way into fringe culture, bars, and even healthcare investors' hands. But how viable is it in the greater market?


Chances are you haven't crossed paths with the niche alternative medicine. The root of the plant is used in creating a thick-textured drink.


When consumed, a kava drinker experiences muscle relaxation, sedation, anaesthetic effects, and feelings of euphoria. Kava is also known to provide measures in combatting depression and anxiety.


For many years, curious globetrotters would have to visit the Pacific Islands in person to get a taste.

However, the past decade has seen the properties of kava marketed to greater western consumers through sprays and even pill forms.


A stand out in the Australian market has flashed its teeth — Fiji Kava.


The small cap company most recently closed shares at 11 cents each in a $6.97 million valuation — pushing the muscle relaxant properties in a pill form.


According to Fiji Kava, the global alternative medicine market is expected to reach a roughly $310 billion valuation by 2026. The company is looking to break into this market with its choice of kava strain known as "Noble".


"There is a major resurgence of global demand for kava, with unprecedented interest shown in our Noble kava extracted products in capsule and powdered forms," Fiji Kava Founder and Managing Director Zane Yoshida said.


Fiji Kava Founder Zane Yoshida
Image sourced from Youtube

Kava is commonly grouped into two major categories: Noble and Tudei.


Tudei kava is referred to as being much stronger than Noble kava and more likely to cause drinkers nausea and overwhelming sensations.


Fiji Kava is the first foreign company in the industry to gain approval from the Fijian Government. Today it operates a tissue culture lab and a 111-acre farm on Fiji's Ovalau island.


Recently Fiji Kava got major recognition from the Australian Government, softening trade restrictions on the alternative medicine.


The Fijian island of Ovalau

"The recent relaxation on kava imports by the Australian Federal government further supports this resurgence," Zane said.


Now the Fiji Kava pills are even being sold through popular web-shop Amazon.


Today the company ear marked its latest accomplishment, signing a memorandum with an Australian natural health market leader — Oborne Health Suppliers.


"We selected Oborne Health Suppliers based on their leadership and wholistic offering, and we are confident that together we can deliver customer service and support at both an individual retailer and key retail banners nationally across the Natural, Traditional and Complementary Health channel," Zane added.


Oborne distributes its repertoire of natural medicines to health practitioners, health food stores and anything in between.

This deal will act as a gateway for Fiji Kava to reaching further naturopaths, specialists, herbalists, doctors, and chiropractors.


Oborne Health boasts 29 years of experience in the industry and sources products from over 300 suppliers.

Oborne Health Supplies Director Barry Oborne had words of encouragement to add today.


"We are very excited to be working with Fiji Kava, and be distributing their products across our national network of healthcare professionals, to meet the growing demand for kava within our network," he said.


Shares in Fiji Kava have undergone a 10 per cent premium today to trade at an even 11 cents each.


28th July 2020 - The Market Herald

FIJ PARTNERS WITH PHAMA PLUS PROGRAM

arrow-down-2 Created with Sketch.

7th July 2020 - The Market Herald


  • Fiji Kava (FIJ) has partnered with the Pacific Horticultural and Agricultural Market Access (PHAMA) Plus Program to strengthen kava export opportunities 
  • Fiji Kava's subsidiary, South Pacific Elixirs, will work with PHAMA Plus to boost the sustainable production and distribution of kava from Fiji
  • The partnership will also see South Pacific Elixirs and PHAMA Plus work on design and installation of commercial kava nurseries in Fiji
  • This is to sustainably mass-produce kava root to meet the growing market
  • Noble kava has proven medicinal and relaxation benefits and the global market is expected to exceed US$210 billion by 2026
  • Company shares have risen 3.85 per cent and are trading for 8.1 cents each

Fiji Kava (FIJ) has partnered with the Pacific Horticultural and Agricultural Market Access (PHAMA) Plus Program to strengthen kava export opportunities.


Fiji Kava's subsidiary, South Pacific Elixirs, will work with PHAMA Plus to ensure the high-quality, sustainable commercial production and distribution of Fijian kava to global export markets.


This includes utilising the company's tissue culture lab, which is a world-first used to propagate disease-free plants.

"Fiji Kava's world-first tissue culture laboratory and its network of hundreds of local Fijian farmers ensures that our supply chain is uniquely positioned to support this marquee initiative between the two countries," Fiji Kava Founder and CEO Zane Yoshida said.

Fiji Kava is an Australian-Fijian medicinal kava company that produces natural 'noble kava' products.


There are two types of kava — non-noble and noble. In Fiji, only noble kava can be found and is commonly used for its medicinal and relaxation benefits. 


Unlike its non-noble counterpart, noble kava is perfectly safe for consumption and doesn't contain a high concentration of harmful chemicals. Noble kava, especially when the root is extracted using a freshwater method, reduces the chance of negative side effects such as nausea.


"It's an honour to be chosen as the inaugural Fijian partner for the PHAMA Plus program in Fiji. We recognise the importance of this partnership to the Fijian kava community and the major opportunity which exists to export our high-quality, disease-free kava supply around the world," Zane said.


South Pacific Elixirs and PHAMA Plus will partner on design, procurement and installation of commercial kava nurseries in Fiji. Initially, two nurseries in Ovalau and Vanua Levu will be established.


These nurseries will be optimised for the mass production of kava plants which will be distributed to the subsidiary's network of contracted farmers.


This is set to meet the growing global demand for kava, which is expected to exceed US$210 billion (roughly A$301.3 billion) by 2026. 

"Improving the quality of kava is a priority for PHAMA Plus and by partnering with an established leader in the Fijian kava industry, we are able to more effectively progress the significant export opportunities that exist across international markets for higher volumes of noble kava to benefit both exporters and local growers," PHAMA Plus National Export Market Systems Facilitator Navitalai Tuivuniwai said.


The partnership will also focus on sustainable agricultural practices. Initiatives will be implemented to strengthen South Pacific Elixirs' supply chain. 


These initiatives include climate resilience technologies, production planning, expanding capacity, technology transfer, harvesting schedules, quality certification and overall standardisation. 


This partnership has also been backed by the Australian Government, who recognises the importance of the Fijian kava industry and its social and economic importance to the nation's agriculture.


Company shares have risen 3.85 per cent and are trading for 8.1 cents each at 10:48 am AEST.


7th July 2020 - The Market Herald

VIDEO

arrow-down-2 Created with Sketch.

The Market Herald Live News Bulletin - Momentum through FY2020

ABOUT FIJI KAVA

arrow-down-2 Created with Sketch.

Fiji Kava is a medicinal Noble kava company based in Australia, providing a natural solution to calm and soothe nerves, support muscle relaxation, increase mind relaxation and induce sleep. Fiji Kava is the first and only foreign company with approval from the Fijian Government to operate in the kava industry and is the world’s first listed kava company (ASX:FIJ).


The Company has complete control over its vertically integrated supply chain, in a true farm-to-shelf operation and has established an 111-acre “Nucleus Farm” in Levuka, on the island of Ovalau, Fiji. The high-quality Noble kava cultivars that Fiji Kava grows, harvests and processes, are among the most consistent and finest in the world, with few – if any – who can achieve kava at this level.



Widely recognised as supplying the world’s most trusted Noble kava, Fiji Kava is now focused on bringing the secret elixir of Fiji’s world-famous joyful, calm and relaxed culture to the world by distributing a range of scientifically researched, TGA and FDA compliant Noble kava extract products throughout western markets.


 In Australia, this includes Noble kava extract capsules, whereas in Fiji, New Zealand and the United States of America, the range also includes instant powders and shots (with new exciting products currently undergoing development and testing).


In Fiji, Fiji Kava also operates under the Taki Mai brand (with its inception in 2014) with stockists, to name a few,  including Tappoo and Jacks of Fiji.


 


FIND RELIEF TODAY!

The medicinal benefits of kava have been traditionally used in Pacific Islander and Western herbal medicine to promote sleep, relax the body and calm and soothe the nerves.


Our kava possesses specific % levels of kavalactones and other desirable profiles found from our 13 years of research into 200 varieties of kava across the South Pacific.


As well as being TGA and FDA compliant and listed as a complementary medicine in Australia, kava is also sold as a dietary supplement in most other international markets.


Add to Cart

 Browse Shop


Visit Fiji Kava's Website Here

(20min delay)
Last
11.0¢
Change
0.005(4.76%)
Mkt cap ! $14.29M
Open High Low Value Volume
11.0¢ 11.0¢ 11.0¢ $1.87K 17K

Buyers (Bids)

No. Vol. Price($)
2 79363 11.0¢
 

Sellers (Offers)

Price($) Vol. No.
12.0¢ 11111 1
View Market Depth
Last trade - 15.25pm 13/05/2021 (20 minute delay) ?
FIJ (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.